Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00885066 | Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 30 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03138720 | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer | completed | Phase 2 | 40 | HonorHealth Research InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01692873 |
| Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors(PACAomics) |
| completed |
| N/A |
| 274 |
| Institut Paoli-CalmettesOTHER |
| 1 |
| Apr 21, 2026 |
| clinicaltrials |
| NCT07542782 | Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer(PRONPaC) | completed | — | 2,048 | Medizinische Hochschule Brandenburg Theodor FontaneOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04128332 | Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer(PORTICO-SABR) | completed | N/A | 10 | CCTU- Cancer ThemeOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04899739 | Intraoperative Endoscopic Ultrasound for Pancreatic Cancer(EchoSurg) | completed | N/A | 33 | IHU StrasbourgOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04924062 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | completed | Phase 3 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05247164 | EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients(EUPhORIC) | completed | N/A | 23 | IRCCS San RaffaeleOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 21 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03403049 | Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 14 | Montefiore Medical CenterOTHER | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04241367 | Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy | completed | — | 420 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT04834674 | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04132505 | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07319767 | Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors | completed | — | 120 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05617872 | Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic Ultrasound | completed | N/A | 75 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05438927 | Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer | completed | N/A | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06630910 | New Technique of Pancreaticojejunostomy During Whipple Operation(whipple) | completed | N/A | 48 | Theodor Bilharz Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05068752 | Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | completed | Phase 2 | 10 | HonorHealth Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05586516 | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 16 | iOncturaINDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT07497204 | Splenic Artery Infusion Chemotherapy vs Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer(SAIC-PBTC) | completed | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03601923 | Niraparib in Patients With Pancreatic Cancer | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)(KEYNOTE-966) | completed | Phase 3 | 1,069 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 24, 2026 | clinicaltrials |
| NCT04165018 | Prospective Study FNB, Is It Time To Abandon Cytological Assessment((FACET)) | completed | — | 52 | Baylor College of MedicineOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | completed | Phase 2 | 36 | Crinetics Pharmaceuticals Inc.INDUSTRY | 7 | Mar 19, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT07479264 | A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma | completed | — | 169 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02648282 | Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer | completed | Phase 2 | 58 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04301778 | Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06381648 | Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)(LyMIC) | completed | — | 230 | City of Hope Medical CenterOTHER | 2 | Mar 13, 2026 | clinicaltrials |
| NCT07224737 | Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.(EXOMIC) | completed | — | 230 | City of Hope Medical CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07225452 | An Exosomal miRNA-based Liquid Biopsy for ICC Detection(LUMIC) | completed | — | 535 | City of Hope Medical CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04194268 | Pancreatic Cancer and Carbon Ion Radiotherapy(PACK) | completed | N/A | 25 | University Hospital HeidelbergOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 46 | Yale UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06184867 | Choices About Genetic Testing And Learning Your Risk With Smart Technology(CATALYST) | completed | N/A | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07446946 | Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)(POlig) | completed | — | 68,303 | Richard HungerOTHER | 0 | Mar 3, 2026 | clinicaltrials |
| NCT02110498 | Early Detection of Pancreatic Cystic Neoplasms | completed | — | 3,000 | Johns Hopkins UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04238715 | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion | completed | Phase 2 | 63 | Eisai Co., Ltd.INDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT01202136 | The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study(PCyst) | completed | — | 477 | Johns Hopkins UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | completed | Phase 1 / Phase 2 | 51 | Lokon Pharma ABINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2026source: clinicaltrials